Drug Type Autologous CAR-T |
Synonyms 15. CAR-T, GLYCAR, GPC3-CAR T cells |
Target |
Action modulators |
Mechanism GPC3 modulators(Glypican-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 1 | United States | 03 Apr 2025 | |
Recurrent Glioblastoma | Phase 1 | United States | 03 Apr 2025 | |
Endodermal Sinus Tumor | Phase 1 | United States | 24 May 2024 | |
Liposarcoma | Phase 1 | United States | 24 May 2024 | |
Rhabdoid Tumor | Phase 1 | United States | 24 May 2024 | |
Rhabdomyosarcoma | Phase 1 | United States | 24 May 2024 | |
Wilms Tumor | Phase 1 | United States | 24 May 2024 | |
Hepatoblastoma | Phase 1 | - | 01 Jan 2020 | |
GPC3 Positive Hepatocellular Carcinoma | Phase 1 | United States | 28 Mar 2019 | |
Hepatocellular Carcinoma | Phase 1 | United States | 17 Dec 2018 |
Phase 1 | - | jlwdteaeuk(hhwrrksvjo) = tqbngjokvk cyofehetou (ecmzxwgltx ) View more | Positive | 27 Dec 2024 |